Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial

Conclusions: The majority of clinically defined HER2-positive tumors were classified as HER2-enriched or luminal using the Prosigna algorithm. Intrinsic subtype alone cannot replace conventional histopathological evaluation of HER2 status because many tumors that are classified as luminal A or luminal B will benefit from adjuvant trastuzumab if that subtype is accompanied by HER2 overexpression. However, among tumors that overexpress HER2, we speculate that assessment of intrinsic subtype may influence treatment, particularly with respect to evaluating alternative therapeutic approaches for that subset of HER2-positive tumors of the basal-like subtype.

Source: JNCI - October 27, 2016 Category: Cancer & Oncology Authors: Perez, E. A., Ballman, K. V., Mashadi-Hossein, A., Tenner, K. S., Kachergus, J. M., Norton, N., Necela, B. M., Carr, J. M., Ferree, S., Perou, C. M., Baehner, F., Cheang, M. C. U., Thompson, E. A. Tags: Article Source Type: research